Membrane Proteins Screening Array, MPSA AB5000

De-Risk the off-target interactions of your antibody drug for IND application.

MPSA-AB5000 Introduction

Membrane Proteins Screening Array AB5000 service

 

MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to membrane proteins. To provide the highest level of sensitivity, MPSA-AB5000 uses luciferase reporter cell line detection.[/caption]

MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to membrane proteins. To provide the highest level of sensitivity, MPSA-AB5000 uses luciferase reporter cell line detection.[/caption]

The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. The lack of suitable methods to identify the targets of functional antibodies and ligands result in drug safety accidents and the abandonment of previous studies.

KYinno’s Membrane Proteins Screening Array (MPSA-AB5000) is an excellent solution for antibody specificity screening which enable early off-target screening and can de-risk the antibody drug development program.

Full Coverage of Human Membrane Protein Library

  • The MPSA-AB5000 makes use of more than 5000 unique human membrane protein, including receptors, transporters, enzymes, miscellaneous, and others.
  • Natively expressed in live cells ensuring native protein conformation.

High Sensitivity Reporter System Detection

  • Wash-free strategy reduces false negatives.
  • Signal amplification makes large discrimination.
  • High throughput microplate system guarantees best stability and creditability.

Compatibility with Different Types of Biologic Therapeutics:

 

  • MPSA-AB5000 is compatible with monoclonal antibodies, bispecific antibodies, ADC, orphan protein and antibody, as well as CAR-T cell therapies.

Successfully Screened Off-target Molecules

  • Ultrashort turnaround for data report
  • Competitively priced

MPSA-AB5000 is rapid, simple and highly sensitive by measuring binding via reporter cell line and can determine specificity and preclinical safety of biotherapeutics conveniently.

All Antibody Discovery Services

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.

Using antibodies with high specificity, we guarantee precise binding targets for CAR-T cells and biologics. This meticulous approach is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.
ai drug discovery service
Nanobodies, known for their small molecular weight, high affinity, stability, permeability, and cost-effectiveness, have demonstrated tremendous potential in disease …